[{"id":"400ee27d-f37b-4084-97df-9e5dd47e2318","acronym":"","url":"https://clinicaltrials.gov/study/NCT03792074","created_at":"2021-01-18T18:44:55.774Z","updated_at":"2024-07-02T16:37:04.276Z","phase":"Phase 3","brief_title":"To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03792074","lead_sponsor":"Sinocelltech Ltd.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • ALK fusion • EGFR L861Q • EGFR G719X","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • ALK fusion • EGFR L861Q • EGFR G719X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • Ambezhu (bevacizumab biosimilar)"],"overall_status":"Unknown status","enrollment":" Enrollment 560","initiation":"Initiation: 02/01/2019","start_date":" 02/01/2019","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2019-01-03"}]